Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:NVEI) was changed from Market Perform to Outperform.
(MT Newswires cīenzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 JPMorgan Starts RAPT Therapeutics at Overweight with $61 Price TargetĠ9:18 AM EST, (MT Newswires) - RAPT Therapeutics (RAPT) has an average rating of buy and price targets ranging from $49 to $72, according to analysts polled by Capital IQ.
was incorporated in 2015 and is headquartered in South San Francisco, California. and changed its name to RAPT Therapeutics, Inc. The company was formerly known as FLX Bio, Inc. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development.
The company’s lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
RAPT STOCK NEWS TRIAL
Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases.
0 kommentar(er)
